Total
0
Shares
CEO, Rod Matheson Source: marvelbiotechnology.com
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Marvel Biosciences Corp. (MRVL) initiated a new program to identify and develop novel safe agents that promote neuroplasticity without the abuse potential or hallucinations of psychedelics
  • Psychedelics being researched include ketamine, LSD, DMT and psilocybin
  • Rod Matheson, CEO of Marvel, said the new program has potential to treat a span of different neurodegenerative disorders such as ALS, Alzheimer’s and Parkinson’s disease
  • Molecules Marvel has developed are fast acting, orally available, water soluble with no sign of hallucinations
  • Marvel Biosciences Corp. (MRVL) is up 5.55 per cent and is trading at $0.28 per share at 12:37 p.m. ET

Marvel Biosciences (MRVL) has launched a program to identify and develop agents that promote neuroplasticity without the risks or side effects of psychedelics.

Psychedelics are being researched including ketamine, LSD, DMT and psilocybin.

Marvel has identified a series of compounds inspired by known psychedelic molecules that appear to be effective as anti-depressants in preclinical testing.

The compounds were given for seven days, and preliminary evidence found multiple molecules with the same core structure capable of reducing depressive symptoms measured in the widely accepted “forced swim test”.

Early indications are considered extremely constructive with the test producing two positive indicators that exhibited potential for treatment.

Rod Matheson, CEO of Marvel, said the new program has the potential to treat a span of different neurodegenerative disorders such as ALS, Alzheimer’s and Parkinson’s disease.

“This program is in addition to our current development program of our caffeine inspired lead compound asset MB-204 being developed for neurological conditions…MB-204 is in the manufacturing development phase and advancing well towards the clinic,” he said.

Some features of the first class of molecules Marvel has developed include that it is fast-acting, orally available, water-soluble, no sign of hallucinations and significantly better results than Prozac.

Dr. Mark Williams, President and Chief Science Officer of Marvel, said the results present a “compelling opportunity” for expanding Marvel’s product portfolio.

“We need to further characterize and expand upon the first set of hits we have identified…We are strong advocates for the use of psychedelic treatments to address mental health issues, yet it is critical that they are put through rigorous testing to ensure efficacy and safety for patients,” he said.

Marvel Biosciences Corp. (MRVL) is up 5.55 per cent and is trading at $0.28 per share at 12:37 p.m. ET.

More From The Market Herald
Red Light Holland - Director and CEO, Todd Shapiro (right).

" Red Light Holland (CSE:TRIP) expands footprint in Q2

Red Light Holland (TRIP) has reported Q2 results highlighted by a 64-per-cent increase in gross profit from Q1.

" Psyence Group (CSE:PSYG) to speak at the annual Global Wellness Summit

Psyence Group (PSYG) will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit.
The Market Herald Video

" Algernon (CSE:AGN) announces positive feedback on its planned Phase 1/2a DMT Human Stroke Study

Algernon (AGN) received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency.
The Market Herald Video

" Psyched Wellness announces the Amanita Muscaria mushroom has been added to the Natural Health Products Ingredients Database (NHPID) of Canada

Psyched Wellness (PSYC) announced that the Amanita Muscaria mushroom has been added to the Natural Health Products Ingredients Database (NHPID) of Canada.